General Info

Established in 1993, Ciphergen Biosystems initial focus was protein research, specifically protein ladder sequencing technologies. In 2004, it launched the ProteinChip System Series 4000, which enables biomarker discovery, purification, identification and quantitative assays at the benchtop. Ciphergen s diagnostics division is known for its diagnostic efforts in oncology. At the 2004 American Association of Cancer Research meeting, nearly 50 scientific papers or presentations were made based on the ProteinChip technology. The company s clients include Proctor & Gamble, Tufts University, Bayer, Johnson & Johnson, Cornell Medical School and Stanford University. The company established the Biomarker Discovery Center facilities in Fremont, Calif.; Malvern, Pa.; Copenhagen, Denmark; and Yokohama, Japan, to collaborate with its pharmaceutical clients and to do independent work for its own account aimed at the discovery and validation of biomarkers that may have clinical and preclinical utility. Ciphergen Biosystems is headquartered in Fremont, Calif.